A Phase 4 interventional study of Rivaroxaban and Standard-of-care in Pulmonary Embolism, sponsored by Janssen Scientific Affairs, LLC. Completed at 50 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-01.
Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing rivaroxaban in Pulmonary Embolism — 4 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Pulmonary Embolism.
Among the 20 studies testing rivaroxaban in Pulmonary Embolism, this one is the 13th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 4, and was the 9th registered.
832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.
Browse Pulmonary Embolism studies →4 of the 20 studies testing rivaroxaban in Pulmonary Embolism are open now, in 8 countries. Recruiting first, the newest first:
Prof. Stavros Konstantinides, MD · Sites in Austria, Germany
Ages 18–85
Medical University of Gdansk · Sites in Poland
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
Drahomir Aujesky · Sites in Belgium, Canada, France and 2 more countries
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8 · Phase 4 6
First in 2004; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is below the median of 174 across 429 interventional studies indexed under Pulmonary Embolism.
Median enrollment 241 across the 20 interventional studies. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Scientific Affairs, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Scientific Affairs, LLC is the lead sponsor of 41 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Johnson & Johnson has 1 study filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
2 of the studies testing rivaroxaban in Pulmonary Embolism that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611319Phase 3Prof. Stavros Konstantinides, MDENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | 2027-03 |
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing rivaroxaban in Pulmonary Embolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants who are discharged from the Emergency Department (ED) to the home environment and treated with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or venous thromboembolism (VTE) events through Day 30 compared to participants who are treated with initial hospitalization and standard-of-care.
This is a randomized (study medication is assigned by chance), open-label (all people know the identity of the intervention), parallel-group, multicenter (study conducted at multiple sites) study to evaluate that low risk PE participants who are discharged from the ED and treated with rivaroxaban compared to participants who are treated with initial hospitalization and standard-of-care. The study consists of a Screening and Randomization Period, followed by a 90-day open-label treatment period, and an end of study/early withdrawal (EOS) visit. The duration of study participation for each participant is approximately 3 months. The participants will be randomized in a 1:1 ratio to one of two treatments. Safety will be monitored during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.
Drug: Rivaroxaban
Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.
Drug: Standard-of-care
Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
Standard-of-care as per local protocol and defined by the medical team caring for the participant.
Mean Duration of Hospitalization
Mean number of days of initial inpatient hospitalization (beginning from randomization to discharge from the hospital) plus any subsequent hospitalization(s) related to bleeding and/or venous thromboembolism (VTE) events up to 30 days were calculated.
Time frame: Up to Day 30
Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death
Reoccurrence of symptomatic, objectively confirmed VTE, defined as recurrent pulmonary embolism (PE) or new or recurrent deep vein thrombosis (DVT) (including symptomatic upper extremity DVT) or VTE related death were analyzed.
Time frame: Up to 7, 14, 30, and 90 Days
Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding
Percentage of participants of unplanned hospitalization for VTE symptoms or bleeding-related hospital or physician visits were analyzed.
Time frame: Up to 7, 14, 30 and 90 Days
Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason
Mean combined duration of Initial and subsequent ED Stay and hospitalization for any reason within 30 and 90 days from randomization was analyzed.
Time frame: Up to 30 and 90 Days
Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS)
ACTS is defined as a validated measure for assessing treatment satisfaction. The ACTS comprised of 2 subscales: Burdens (13 items: Item 1 to 13 \[how much of limitation from taking part in vigorous physical activities, limitation from usual activities, bothered by bruising, bothered to avoid other medicines, limitation to diet, daily hassle, occasional hassle, difficult to follow treatment, time-consuming, worrying, frustrating, burden, negative impact on life respectively) and Benefits (4 items: Items 14 to 17 for evaluating confidence, reassurance, satisfaction, positive impact respectively) as a result of anti-clot treatment. The treatment experience scores ranged from 'Not at all' to 'Extremely' on a 5-point Likert scale (psychometric rating); higher scores indicate greater satisfaction with treatment.
Time frame: Day 90
Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire
The Satisfaction to Site-of-Care Questionnaire (standard-of-care versus early discharge on rivaroxaban therapy) was administered after 7 days on anticoagulant therapy. Satisfaction to Site-of-Care (hospitalization versus home care) rates the participant's level of satisfaction to care and location with care received as well as preference to location of care provided. Participants rated the 3 items of this scale of 1=Very satisfied; 2=Quite satisfied; 3=Neither; 4=Quite dissatisfied; and 5=Very dissatisfied for satisfaction questions and for the 1 preference question responses included 1=In the hospital; 2=In the community; and 3=No preference. Higher score indicates more level of satisfaction.
Time frame: Day 7
| Milestone | Rivaroxaban | Standard-of-care |
|---|---|---|
| Started | 51 | 63 |
| Treated | 49 | 63 |
| Completed | 44 | 55 |
| Not completed | 7 | 8 |
| Withdrew: Adverse event | 4 | 0 |
| Withdrew: Lost to follow-up | 3 | 4 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Other | 0 | 1 |
Mean number of days of initial inpatient hospitalization (beginning from randomization to discharge from the hospital) plus any subsequent hospitalization(s) related to bleeding and/or venous thromboembolism (VTE) events up to 30 days were calculated.
| Days | Rivaroxaban | Standard-of-care |
|---|---|---|
| Mean Duration of Hospitalization | 0.191 ± 0.6862 | 1.393 ± 1.9642 |
Reoccurrence of symptomatic, objectively confirmed VTE, defined as recurrent pulmonary embolism (PE) or new or recurrent deep vein thrombosis (DVT) (including symptomatic upper extremity DVT) or VTE related death were analyzed.
| Percentage of participants | Rivaroxaban | Standard-of-care |
|---|---|---|
| Up to 7 Days | 0 | 0 |
| Up to 14 Days | 0 | 0 |
| Up to 30 Days | 0 | 0 |
| Up to 90 Days | 0 | 0 |
Percentage of participants of unplanned hospitalization for VTE symptoms or bleeding-related hospital or physician visits were analyzed.
| Percentage of Participants | Rivaroxaban | Standard-of-care |
|---|---|---|
| Up to 7 Days | 0 | 0 |
| Up to 14 Days | 2 | 0 |
| Up to 30 Days | 3.9 | 1.6 |
| Up to 90 Days | 3.9 | 6.3 |
Mean combined duration of Initial and subsequent ED Stay and hospitalization for any reason within 30 and 90 days from randomization was analyzed.
| Days | Rivaroxaban | Standard-of-care |
|---|---|---|
| Within 30 Days | 0.679 ± 2.0894 | 1.513 ± 1.9952 |
| Within 90 Days | 0.764 ± 2.1829 | 1.812 ± 2.714 |
ACTS is defined as a validated measure for assessing treatment satisfaction. The ACTS comprised of 2 subscales: Burdens (13 items: Item 1 to 13 \[how much of limitation from taking part in vigorous physical activities, limitation from usual activities, bothered by bruising, bothered to avoid other medicines, limitation to diet, daily hassle, occasional hassle, difficult to follow treatment, time-consuming, worrying, frustrating, burden, negative impact on life respectively) and Benefits (4 items: Items 14 to 17 for evaluating confidence, reassurance, satisfaction, positive impact respectively) as a result of anti-clot treatment. The treatment experience scores ranged from 'Not at all' to 'Extremely' on a 5-point Likert scale (psychometric rating); higher scores indicate greater satisfaction with treatment.
| Percentage of participants | Rivaroxaban | Standard-of-care |
|---|---|---|
| Item 1: Not at all | 51.1 | 61.8 |
| Item 1: A little | 40 | 21.8 |
| Item 1: Moderately | 6.7 | 10.9 |
| Item 1: Quite a bit | 2.2 | 1.8 |
| Item 1: Extremely | 0 | 3.6 |
| Item 2: Not at all | 77.8 | 70.9 |
| Item 2: A little | 13.3 | 20 |
| Item 2: Moderately | 6.7 | 7.3 |
| Item 2: Quite a bit | 2.2 | 0 |
| Item 2: Extremely | 0 | 1.8 |
| Item 3: Not at all | 71.1 | 65.5 |
| Item 3: A little | 22.2 | 21.8 |
| Item 3: Moderately | 2.2 | 5.5 |
| Item 3: Quite a bit | 4.4 | 5.5 |
| Item 3: Extremely | 0 | 1.8 |
| Item 4: Not at all | 60 | 52.7 |
| Item 4: A little | 33.3 | 20 |
| Item 4: Moderately | 4.4 | 9.1 |
| Item 4: Quite a bit | 2.2 | 10.9 |
| Item 4: Extremely | 0 | 7.3 |
| Item 5: Not at all | 80 | 60 |
| Item 5: A little | 17.8 | 16.4 |
| Item 5: Moderately | 0 | 16.4 |
| Item 5: Quite a bit | 2.2 | 7.3 |
| Item 5: Extremely | 0 | 0 |
| Item 6: Not at all | 75.6 | 56.4 |
| Item 6: A little | 20 | 25.5 |
| Item 6: Moderately | 2.2 | 5.5 |
| Item 6: Quite a bit | 2.2 | 12.7 |
| Item 6: Extremely | 0 | 0 |
| Item 7: Not at all | 73.3 | 45.5 |
| Item 7: A little | 22.2 | 30.9 |
| Item 7: Moderately | 4.4 | 20 |
| Item 7: Quite a bit | 0 | 1.8 |
| Item 7: Extremely | 0 | 1.8 |
| Item 8: Not at all | 82.2 | 78.2 |
| Item 8: A little | 15.6 | 12.7 |
| Item 8: Moderately | 0 | 7.3 |
| Item 8: Quite a bit | 2.2 | 1.8 |
| Item 8: Extremely | 0 | 0 |
| Item 9: Not at all | 84.4 | 74.5 |
| Item 9: A little | 15.6 | 21.8 |
| Item 9: Moderately | 0 | 1.8 |
| Item 9: Quite a bit | 0 | 1.8 |
| Item 9: Extremely | 0 | 0 |
| Item 10: Not at all | 48.9 | 43.6 |
| Item 10: A little | 28.9 | 16.4 |
| Item 10: Moderately | 8.9 | 18.2 |
| Item 10: Quite a bit | 11.1 | 10.9 |
| Item 10: Extremely | 2.2 | 10.9 |
| Item 11: Not at all | 77.8 | 60 |
| Item 11: A little | 17.8 | 16.4 |
| Item 11: Moderately | 4.4 | 7.3 |
| Item 11: Quite a bit | 0 | 9.1 |
| Item 11: Extremely | 0 | 7.3 |
| Item 12: Not at all | 84.4 | 64.8 |
| Item 12: A little | 15.6 | 18.5 |
| Item 12: Moderately | 0 | 9.3 |
| Item 12: Quite a bit | 0 | 3.7 |
| Item 12: Extremely | 0 | 3.7 |
| Item 13: Not at all | 64.4 | 54.5 |
| Item 13: A little | 28.9 | 18.2 |
| Item 13: Moderately | 4.4 | 14.5 |
| Item 13: Quite a bit | 2.2 | 7.3 |
| Item 13: Extremely | 0 | 5.5 |
| Item 14: Not at all | 4.4 | 5.5 |
| Item 14: A little | 8.9 | 7.3 |
| Item 14: Moderately | 20 | 21.8 |
| Item 14: Quite a bit | 26.7 | 38.2 |
| Item 14: Extremely | 40 | 27.3 |
| Item 15: Not at all | 4.4 | 5.6 |
| Item 15: A little | 8.9 | 5.6 |
| Item 15: Moderately | 20 | 24.1 |
| Item 15: Quite a bit | 35.6 | 42.6 |
| Item 15: Extremely | 31.1 | 22.2 |
| Item 16: Not at all | 8.9 | 5.5 |
| Item 16: A little | 2.2 | 9.1 |
| Item 16: Moderately | 15.6 | 9.1 |
| Item 16: Quite a bit | 33.3 | 45.5 |
| Item 16: Extremely | 40 | 30.9 |
| Item 17: Not at all | 2.2 | 7.3 |
| Item 17: A little | 13.3 | 7.3 |
| Item 17: Moderately | 17.8 | 18.2 |
| Item 17: Quite a bit | 28.9 | 43.6 |
| Item 17: Extremely | 37.8 | 23.6 |
The Satisfaction to Site-of-Care Questionnaire (standard-of-care versus early discharge on rivaroxaban therapy) was administered after 7 days on anticoagulant therapy. Satisfaction to Site-of-Care (hospitalization versus home care) rates the participant's level of satisfaction to care and location with care received as well as preference to location of care provided. Participants rated the 3 items of this scale of 1=Very satisfied; 2=Quite satisfied; 3=Neither; 4=Quite dissatisfied; and 5=Very dissatisfied for satisfaction questions and for the 1 preference question responses included 1=In the hospital; 2=In the community; and 3=No preference. Higher score indicates more level of satisfaction.
| Percentage of participants | Rivaroxaban | Standard-of-care |
|---|---|---|
| Satisfaction level: Very Satisfied | 60.4 | 62.7 |
| Satisfaction level: Quite Satisfied | 33.3 | 23.7 |
| Satisfaction level: Neither | 4.2 | 6.8 |
| Satisfaction level: Quite Dissatisfied | 2.1 | 5.1 |
| Satisfaction level: Very Dissatisfied | 0 | 1.7 |
| Location of care: Very Satisfied | 62.5 | 59.3 |
| Location of care: Quite Satisfied | 33.3 | 30.5 |
| Location of care: Neither | 4.2 | 6.8 |
| Location of care: Quite Dissatisfied | 0 | 1.7 |
| Location of care: Very Dissatisfied | 0 | 1.7 |
| Preference of care: In the Hospital | 18.8 | 47.5 |
| Preference of care: In the Community | 50 | 40.7 |
| Preference of care: No Preference | 31.3 | 11.9 |
Collected over Approximately 2.5 years. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban | 0/49 (0%) | 5/49 (10.2%) | 15/49 (30.6%) |
| Standard-of-care | 0/63 (0%) | 7/63 (11.1%) | 13/63 (20.6%) |
| Event | Rivaroxaban | Standard-of-care |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/49 | 3/63 |
| Atrial FibrillationCardiac disorders | 1/49 | 0/63 |
| Chest PainGeneral disorders | 1/49 | 0/63 |
| PainGeneral disorders | 1/49 | 0/63 |
| Device Related InfectionInfections and infestations | 1/49 | 0/63 |
| SepsisInfections and infestations | 1/49 | 0/63 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/49 | 0/63 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/49 | 0/63 |
| Systemic Inflammatory Response SyndromeGeneral disorders | 0/49 | 1/63 |
| Embolic PneumoniaInfections and infestations | 0/49 | 1/63 |
| Event | Rivaroxaban | Standard-of-care |
|---|---|---|
| Chest PainGeneral disorders | 5/49 | 3/63 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/49 | 5/63 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 3/49 | 0/63 |
| MenorrhagiaReproductive system and breast disorders | 3/49 | 1/63 |
| HeadacheNervous system disorders | 2/49 | 3/63 |
| SinusitisInfections and infestations | 2/49 | 0/63 |
| Back PainMusculoskeletal and connective tissue disorders | 2/49 | 1/63 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 2/49 | 0/63 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/49 | 1/63 |
| Non-Cardiac Chest PainGeneral disorders | 0/49 | 2/63 |
| Age, Continuous(years) | Rivaroxaban | Standard-of-care | Total |
|---|---|---|---|
| Mean | 49.1 ± 13.27 | 47.6 ± 17.22 | 48.3 ± 15.53 |
| Sex: Female, Male(Participants) | Rivaroxaban | Standard-of-care | Total |
|---|---|---|---|
| Female | 27 | 32 | 59 |
| Male | 24 | 31 | 55 |
| Ethnicity (NIH/OMB)(Participants) | Rivaroxaban | Standard-of-care | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 47 | 60 | 107 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Rivaroxaban | Standard-of-care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 14 | 34 |
| White | 29 | 48 | 77 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Rivaroxaban | Standard-of-care | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| Black or African American | 20 | 14 | 34 |
| Hispanic or Latino | 2 | 2 | 4 |
| Other | 1 | 1 | 2 |
| White | 29 | 48 | 77 |
| Not Hispanic or Latino | 47 | 60 | 107 |
| Region of Enrollment(Participants) | Rivaroxaban | Standard-of-care | Total |
|---|---|---|---|
| UNITED STATES | 51 | 63 | 114 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Mar 2017, 17 months.
Results were first posted in Apr 2018, 1 year after primary completion.
Of 24 phase 4 interventional studies under Pulmonary Embolism, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 82. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Janssen Scientific Affairs, LLC →